Are shrooms addictive?

From WikiPsilocybin, the free psilocybin encyclopedia — a harm-reduction article

This article covers the dependence and abuse potential of psilocybin mushrooms. For side effects, overdose, and general safety, see Are magic mushrooms dangerous?

Psilocybin mushrooms ("shrooms") are not considered addictive in the way that alcohol, nicotine, opioids, or stimulants are. They do not produce physical dependence or a withdrawal syndrome, laboratory animals will not reliably self-administer them, and the rapid tolerance they produce makes daily use self-limiting.^[1][2][4] A comprehensive review of psilocybin against the eight abuse-potential factors of the US Controlled Substances Act concluded that, if approved as a medicine, it would fit Schedule IV, the category for drugs with low abuse potential such as benzodiazepines and zolpidem, rather than Schedule I where it currently sits.^[1]

That does not mean problematic use is impossible. A minority of people use hallucinogens compulsively enough to meet criteria for hallucinogen use disorder, a diagnosis in the DSM-5, and psychological habits can form around any experience a person finds meaningful or escapist.^[5] This article explains the distinction, what the evidence says, and the small number of situations where use of shrooms deserves attention.

The short answer

No, by the standard scientific definitions. The US National Institute on Drug Abuse states that psilocybin is not known to cause physical dependence, and the Drug Enforcement Administration's own drug fact sheet notes that psilocybin does not produce compulsive drug-seeking behaviour in animal models.^[2][6] In the 2010 Lancet multicriteria harm analysis, psilocybin mushrooms scored lowest of 20 drugs on the "dependence" criterion as well as on overall harm.^[7]

The features that make a drug addictive, meaning strong activation of the brain's dopamine reward pathway, escalating use, physical withdrawal, and craving between uses, are weak or absent for psilocybin. Most people who try mushrooms use them a handful of times in their lives; the National Survey on Drug Use and Health consistently finds past-month use to be a small fraction of lifetime use, a pattern opposite to that of addictive drugs.^[8]

What "addictive" means

Addiction researchers distinguish several things that "addictive" can refer to:

• Physical dependence — the body adapts to the drug so that stopping causes a withdrawal syndrome (alcohol, opioids, benzodiazepines).
• Reinforcement — the drug directly activates reward circuitry so that animals and people will work to obtain it repeatedly (cocaine, nicotine).
• Compulsive use — continued use despite harm, loss of control, craving; this is the core of a DSM-5 substance use disorder.
• Psychological habit — reliance on an experience for coping or escape, which can attach to almost any activity.

Psilocybin scores low on the first three and, like any powerful experience, is not immune to the fourth.

The evidence

Animal studies

The standard laboratory test of abuse liability is whether animals will self-administer a drug. Rats and monkeys readily self-administer cocaine, heroin, nicotine, and alcohol. Classic psychedelics, including psilocybin, are among the few psychoactive drugs that animals do not reliably self-administer, and in conditioned place preference tests they produce weak or no preference.^[1][3] Psilocin also does not substantially increase dopamine in the nucleus accumbens, the signature of reinforcing drugs, though it has modest indirect dopaminergic effects.^[3]

Human laboratory and clinical studies

In over two decades of modern clinical trials with more than a thousand participants receiving psilocybin under supervision, no study has reported drug-seeking, craving, or subsequent compulsive use as an outcome.^[1][9] A 2024 meta-analysis of adverse events across classic-psychedelic trials found no cases of dependence.^[9] Follow-up of healthy volunteers in the Johns Hopkins studies found that the most common change in drug use after a high-dose session was a decrease in use of other substances.^[10]

Population data

Among US adults, lifetime use of psilocybin is common (roughly one in ten) but regular use is rare. Analyses of the National Survey on Drug Use and Health found no association between lifetime psychedelic use and increased mental-health problems, and some analyses found psychedelic use associated with lower odds of opioid use disorder.^[8][11]

Tolerance and why it matters

Psilocybin produces rapid and pronounced tolerance. Taking a second dose within a day or two produces a markedly weaker effect, and daily dosing over a few days can abolish the psychedelic effect almost entirely; sensitivity returns after roughly one to two weeks of abstinence.^[4] This is due to down-regulation of the 5-HT_2A receptors psilocin acts on, and it cross-applies to LSD and mescaline.^[4]

Rapid tolerance is one of the main pharmacological reasons psilocybin is hard to use compulsively: escalating daily use simply stops working. It contrasts sharply with drugs such as opioids, where tolerance drives higher doses rather than removing the incentive to redose.

Withdrawal

No physical withdrawal syndrome has been documented for psilocybin in humans or animals, and it is not listed among substances with a recognised withdrawal syndrome in the DSM-5.^[1][5] People who stop after a period of frequent use may notice a "comedown" of fatigue, low mood, or flatness for a day or two after individual sessions, but this is an after-effect of the experience rather than a dependence syndrome, and it does not drive redosing.^[12]

Hallucinogen use disorder

The DSM-5 includes "other hallucinogen use disorder" (distinct from phencyclidine), which can be diagnosed when a person shows a problematic pattern of use, for example spending excessive time obtaining or using, giving up important activities, or continuing despite harm.^[5] Because tolerance counts as one criterion and withdrawal does not apply, the diagnosis rests mostly on behavioural criteria. Prevalence is low: the DSM-5 cites a 12-month prevalence of about 0.1% among US adults, and in treatment-seeking populations hallucinogens are rarely the primary drug.^[5][8]

Warning signs that use has become problematic look the same as for any substance: using more often than intended, using to avoid dealing with life rather than to engage with it, use interfering with work, relationships, or safety, and difficulty stopping despite wanting to. Since psilocybin does not produce physical dependence, the appropriate response is psychological support rather than medical detoxification. The SAMHSA National Helpline (1-800-662-4357) offers free, confidential referrals.^[13]

Does microdosing change the picture?

Microdosing, taking sub-perceptual amounts every few days, is the one pattern of psilocybin use that is habitual by design. Even here, dependence in the pharmacological sense has not been observed, and most protocols build in off-days precisely because of tolerance.^[14] The open questions with microdosing concern efficacy (placebo-controlled studies show most reported benefits are matched by placebo) and the lack of long-term safety data on repeated 5-HT_2B receptor activation, a theoretical cardiac-valve concern, rather than addiction.^[14][15]

Psilocybin as an addiction treatment

Rather than causing addiction, psilocybin is being studied as a treatment for it. In a 2022 randomised trial at NYU, two supervised psilocybin sessions combined with therapy reduced heavy-drinking days in people with alcohol use disorder by 83% over eight months, versus 51% with an active placebo.^[16] A Johns Hopkins pilot study of psilocybin for smoking cessation reported 80% biologically verified abstinence at six months and 60% at 30 months, well above rates for conventional treatments, though the study was small and uncontrolled.^[17] Larger trials in alcohol, tobacco, opioid, and cocaine use disorders are under way.

Harm reduction

Because the addiction risk is low, harm reduction for shrooms focuses on the acute risks covered in Are magic mushrooms dangerous?: mushroom identification, dose, setting, a sober companion, and avoiding combinations with lithium, alcohol, and stimulants. Specific to patterns of use:

• Space sessions apart. Tolerance means redosing within days is largely wasted and adds physical strain without effect. Many experienced users and clinicians suggest weeks to months between full doses.
• Notice the reason. Using to explore, celebrate, or process is different from using to avoid. If mushrooms have become the way you cope with something, that something still needs attention.
• Watch for other substances. People who develop problems around psychedelics frequently have concurrent problematic use of alcohol or cannabis; those are usually the drugs to address first.
• Mental-health history matters more than addiction risk. The main reason to be cautious about repeated use is psychiatric vulnerability, not dependence.

See also

References